Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 9/20 | 0.36 |
| ▸ | HTR3A | P46098 | 9/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19601714 | 0.89 | MGLL (0.36) | MGLLFAAHHTR1AHTR3A | |
| SCHEMBL29417766 | 0.82 | FAAH (0.58) | MGLLFAAH | |
| SCHEMBL19582416 | 0.82 | FAAH (0.58) | MGLLFAAH | |
| SCHEMBL16744506 | 0.78 | CXCR4 (0.48) | HTR1AHTR3A | |
| SCHEMBL19601696 | 0.77 | MGLL (0.50) | MGLLFAAH | |
| SCHEMBL14356017 | 0.75 | HTR1A (0.48) | HTR1AHTR3A | |
| SCHEMBL19601695 | 0.74 | MGLL (0.68) | MGLL | |
| SCHEMBL19601740 | 0.74 | MGLL (0.40) | MGLLHTR2BHTR2C | |
| SCHEMBL19601715 | 0.73 | MGLL (0.67) | MGLL | |
| SCHEMBL19601704 | 0.73 | MGLL (0.67) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327500-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, ACSL6 | MGLL 24/4885FAAH 42/4885HTR1A 4013/4885 |
| US-10030020-B2 | Spirocycle compounds and methods of making and using same | ABHD6, ABHD16A, ACSL6 | MGLL 24/4885FAAH 42/4885HTR1A 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.